Survival for Ovarian Cancer in Europe

The across-country variation did not shrink in the past decade

Willi Oberaigner, Pamela Minicozzi, Magdalena Bielska-Lasota, Claudia Allemani, Roberta De Angelis, Lucia Mangone, Milena Sant

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background. Survival for ovarian cancer is the poorest of all gynaecological cancer sites. Our aim was to present the most up-to-date survival estimate for ovarian cancer by age and morphology and to answer the question whether survival for ovarian cancer improved in Europe during the 1990s. Material and methods. This analysis was performed with data from the EUROCARE database. We considered all adult women diagnosed with ovarian cancer between 1995 and 2002 and life status followed up until the end of 2003. A total of 97 691 cases were contributed by 72 European cancer registries in 24 countries. We estimated the most up-to-date relative survival for a mean of 23 661 patients followed up in 20002003 using the period hybrid approach and described the relative survival trends from the beginning of 1990s. Results and conclusion. Overall, the European age-standardised one-year, five-year and five-year conditional on surviving one-year relative survival were 67.2% (95% CI 66.667.8), 36.1% (95% CI 35.436.8) and 53.7% (95% CI 52.854.7), respectively. Five-year relative survival was 58.6% (95% CI 57.459.8), 37.1% (95% CI 36.138.1) and 20.5% (95% CI 19.121.9) in women aged 1554, 5574 and 7599 years, respectively. The age-standardised five-year relative survival was 38.1% (95% CI 36.939.3) for serous tumours and 51.9% (95% CI 49.054.9) for mucinous cancers and the crude five-year relative survival was 85.6% (95% CI 81.290.0) for germ cell cancers. Overall, the age-standardised five-year relative survival increased from 32.4% (95% CI 31.733.2) in 19911993 to 36.3% (95% CI 35.537.0) in 20002003. There is a need to better understand the reasons for the wide variation in survival of ovarian cancer in Europe. Actions aiming to harmonise the protocols for therapy should contribute to narrowing the wide gap in survival and research on screening and early detection of ovarian cancer should be enforced.

Original languageEnglish
Pages (from-to)441-453
Number of pages13
JournalActa Oncologica
Volume51
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Ovarian Neoplasms
Survival
Neoplasms
Germ Cell and Embryonal Neoplasms
Early Detection of Cancer
Registries
Databases

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Cite this

Survival for Ovarian Cancer in Europe : The across-country variation did not shrink in the past decade. / Oberaigner, Willi; Minicozzi, Pamela; Bielska-Lasota, Magdalena; Allemani, Claudia; De Angelis, Roberta; Mangone, Lucia; Sant, Milena.

In: Acta Oncologica, Vol. 51, No. 4, 04.2012, p. 441-453.

Research output: Contribution to journalArticle

Oberaigner, Willi ; Minicozzi, Pamela ; Bielska-Lasota, Magdalena ; Allemani, Claudia ; De Angelis, Roberta ; Mangone, Lucia ; Sant, Milena. / Survival for Ovarian Cancer in Europe : The across-country variation did not shrink in the past decade. In: Acta Oncologica. 2012 ; Vol. 51, No. 4. pp. 441-453.
@article{b16fc8a8d6b148ff93e13bb1c7b0e3cd,
title = "Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decade",
abstract = "Background. Survival for ovarian cancer is the poorest of all gynaecological cancer sites. Our aim was to present the most up-to-date survival estimate for ovarian cancer by age and morphology and to answer the question whether survival for ovarian cancer improved in Europe during the 1990s. Material and methods. This analysis was performed with data from the EUROCARE database. We considered all adult women diagnosed with ovarian cancer between 1995 and 2002 and life status followed up until the end of 2003. A total of 97 691 cases were contributed by 72 European cancer registries in 24 countries. We estimated the most up-to-date relative survival for a mean of 23 661 patients followed up in 20002003 using the period hybrid approach and described the relative survival trends from the beginning of 1990s. Results and conclusion. Overall, the European age-standardised one-year, five-year and five-year conditional on surviving one-year relative survival were 67.2{\%} (95{\%} CI 66.667.8), 36.1{\%} (95{\%} CI 35.436.8) and 53.7{\%} (95{\%} CI 52.854.7), respectively. Five-year relative survival was 58.6{\%} (95{\%} CI 57.459.8), 37.1{\%} (95{\%} CI 36.138.1) and 20.5{\%} (95{\%} CI 19.121.9) in women aged 1554, 5574 and 7599 years, respectively. The age-standardised five-year relative survival was 38.1{\%} (95{\%} CI 36.939.3) for serous tumours and 51.9{\%} (95{\%} CI 49.054.9) for mucinous cancers and the crude five-year relative survival was 85.6{\%} (95{\%} CI 81.290.0) for germ cell cancers. Overall, the age-standardised five-year relative survival increased from 32.4{\%} (95{\%} CI 31.733.2) in 19911993 to 36.3{\%} (95{\%} CI 35.537.0) in 20002003. There is a need to better understand the reasons for the wide variation in survival of ovarian cancer in Europe. Actions aiming to harmonise the protocols for therapy should contribute to narrowing the wide gap in survival and research on screening and early detection of ovarian cancer should be enforced.",
author = "Willi Oberaigner and Pamela Minicozzi and Magdalena Bielska-Lasota and Claudia Allemani and {De Angelis}, Roberta and Lucia Mangone and Milena Sant",
year = "2012",
month = "4",
doi = "10.3109/0284186X.2011.653437",
language = "English",
volume = "51",
pages = "441--453",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Survival for Ovarian Cancer in Europe

T2 - The across-country variation did not shrink in the past decade

AU - Oberaigner, Willi

AU - Minicozzi, Pamela

AU - Bielska-Lasota, Magdalena

AU - Allemani, Claudia

AU - De Angelis, Roberta

AU - Mangone, Lucia

AU - Sant, Milena

PY - 2012/4

Y1 - 2012/4

N2 - Background. Survival for ovarian cancer is the poorest of all gynaecological cancer sites. Our aim was to present the most up-to-date survival estimate for ovarian cancer by age and morphology and to answer the question whether survival for ovarian cancer improved in Europe during the 1990s. Material and methods. This analysis was performed with data from the EUROCARE database. We considered all adult women diagnosed with ovarian cancer between 1995 and 2002 and life status followed up until the end of 2003. A total of 97 691 cases were contributed by 72 European cancer registries in 24 countries. We estimated the most up-to-date relative survival for a mean of 23 661 patients followed up in 20002003 using the period hybrid approach and described the relative survival trends from the beginning of 1990s. Results and conclusion. Overall, the European age-standardised one-year, five-year and five-year conditional on surviving one-year relative survival were 67.2% (95% CI 66.667.8), 36.1% (95% CI 35.436.8) and 53.7% (95% CI 52.854.7), respectively. Five-year relative survival was 58.6% (95% CI 57.459.8), 37.1% (95% CI 36.138.1) and 20.5% (95% CI 19.121.9) in women aged 1554, 5574 and 7599 years, respectively. The age-standardised five-year relative survival was 38.1% (95% CI 36.939.3) for serous tumours and 51.9% (95% CI 49.054.9) for mucinous cancers and the crude five-year relative survival was 85.6% (95% CI 81.290.0) for germ cell cancers. Overall, the age-standardised five-year relative survival increased from 32.4% (95% CI 31.733.2) in 19911993 to 36.3% (95% CI 35.537.0) in 20002003. There is a need to better understand the reasons for the wide variation in survival of ovarian cancer in Europe. Actions aiming to harmonise the protocols for therapy should contribute to narrowing the wide gap in survival and research on screening and early detection of ovarian cancer should be enforced.

AB - Background. Survival for ovarian cancer is the poorest of all gynaecological cancer sites. Our aim was to present the most up-to-date survival estimate for ovarian cancer by age and morphology and to answer the question whether survival for ovarian cancer improved in Europe during the 1990s. Material and methods. This analysis was performed with data from the EUROCARE database. We considered all adult women diagnosed with ovarian cancer between 1995 and 2002 and life status followed up until the end of 2003. A total of 97 691 cases were contributed by 72 European cancer registries in 24 countries. We estimated the most up-to-date relative survival for a mean of 23 661 patients followed up in 20002003 using the period hybrid approach and described the relative survival trends from the beginning of 1990s. Results and conclusion. Overall, the European age-standardised one-year, five-year and five-year conditional on surviving one-year relative survival were 67.2% (95% CI 66.667.8), 36.1% (95% CI 35.436.8) and 53.7% (95% CI 52.854.7), respectively. Five-year relative survival was 58.6% (95% CI 57.459.8), 37.1% (95% CI 36.138.1) and 20.5% (95% CI 19.121.9) in women aged 1554, 5574 and 7599 years, respectively. The age-standardised five-year relative survival was 38.1% (95% CI 36.939.3) for serous tumours and 51.9% (95% CI 49.054.9) for mucinous cancers and the crude five-year relative survival was 85.6% (95% CI 81.290.0) for germ cell cancers. Overall, the age-standardised five-year relative survival increased from 32.4% (95% CI 31.733.2) in 19911993 to 36.3% (95% CI 35.537.0) in 20002003. There is a need to better understand the reasons for the wide variation in survival of ovarian cancer in Europe. Actions aiming to harmonise the protocols for therapy should contribute to narrowing the wide gap in survival and research on screening and early detection of ovarian cancer should be enforced.

UR - http://www.scopus.com/inward/record.url?scp=84859757842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859757842&partnerID=8YFLogxK

U2 - 10.3109/0284186X.2011.653437

DO - 10.3109/0284186X.2011.653437

M3 - Article

VL - 51

SP - 441

EP - 453

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 4

ER -